Study type: Human research · Status: Verified against declared source
Cost-effectiveness of Cerebrolysin as an add-on treatment for neurorecovery after traumatic brain injury
2025
Study scale: Cost data was collected by the principal investigator, using patient identification numbers, which were previously provided after the patient signed the informed consent.
Abstract only: Open source record
Product or molecular entity relationships
- Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
We employed probabilistic methods for the following cost-effectiveness exercise and computed the incremental cost-effectiveness ratio (ICER) for Cerebrolysin in patients with moderate TBI.
Methods
We employed probabilistic methods for the following cost-effectiveness exercise and computed the incremental cost-effectiveness ratio (ICER) for Cerebrolysin in patients with moderate TBI.
Scale or participants
Cost data was collected by the principal investigator, using patient identification numbers, which were previously provided after the patient signed the informed consent.
Key findings
Traumatic brain injuries (TBIs) are a leading cause of death and long-term disability worldwide, with incidence and injury mechanisms varying by age group and region.
Limitations and uncertainty
In Romania, however, many TBI survivors struggle to regain their pre-injury level of functioning due to limited access to recommended rehabilitation services [17].
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.